Antithyroid drugs

Table   Graphic     exposition period:

Congenital malformations
Adverse outcome VerdictOR 95%CI I2k No. casesNo. exposedpublication bias
All congenital malformations (majors, minors, majors and minors, or unspecified)1.24 [1.10, 1.40]21%12 studies250,10819,467low
Major congenital malformations1.32 [0.95, 1.83]0%6 studies1973,475serious
Urinary malformations1.69 [1.10, 2.61]58%3 studies17,72915,800not evaluable
Genital anomalies1.17 [0.96, 1.41]0%3 studies25,84815,800not evaluable
Respiratory system anomalies1.16 [0.67, 2.01]71%3 studies16,03715,800not evaluable
Congenital heart defects1.33 [0.98, 1.79]71%3 studies77,71315,800not evaluable
Ear, face and neck anomalies1.50 [0.59, 3.82]0%2 studies9172,909not evaluable
Eye defects1.39 [0.70, 2.74]0%2 studies2,4932,909not evaluable
Limb defects1.08 [0.82, 1.41]61%3 studies74,80015,800not evaluable
Severe congenital heart defect0.63 [0.04, 9.47]71%2 studies7392,757not evaluable
Abdominal wall defects3.37 [1.63, 6.96]0%2 studies9332,909not evaluable
Cardiac septal defects1.87 [1.14, 3.06]-1 study1,097not evaluable
Digestive system anomalies1.36 [1.08, 1.71]0%2 studies12,07013,337not evaluable
Nervous system anomalies1.45 [1.06, 2.00]0%2 studies5,88413,337not evaluable
Syndromes and chromosomal abnormalities0.88 [0.34, 2.27]26%2 studies5,5572,909not evaluable
Ano-rectal atresia and stenosis2.04 [0.36, 11.46]53%2 studies1,0562,644not evaluable
Aortic valve atresia/stenosis1.75 [0.07, 44.39]71%2 studies4942,643not evaluable
Carbimazole embryopathy5.24 [0.80, 34.53]50%2 studies2,04813,095not evaluable
Choanal atresia12.25 [5.02, 29.88]0%2 studies119139not evaluable
Omphalocele6.20 [2.78, 13.83]0%2 studies1602,757not evaluable
Situs inversus16.80 [2.99, 94.32]35%2 studies272,757not evaluable
Coarctation of aorta3.99 [1.02, 15.54]-1 study1,13714not evaluable
32 non statistically significant endpoints reported in only one study

Growth parameters and prematurity
Adverse outcome VerdictOR 95%CI I2k No. casesNo. exposedpublication bias
preterm (< 37 weeks)0.95 [0.78, 1.16]3%11 studies6392,427low
low birth weight (< 2500g)1.34 [0.78, 2.32]55%4 studies3071,324not evaluable
small for gestational age (weight)1.06 [0.86, 1.30]0%3 studies5601,400not evaluable
small for gestational age (length)--0 study
small head circumference for gestational age--0 study
2 non statistically significant endpoints reported in only one study

Maternal consequences
Adverse outcome VerdictOR 95%CI I2k No. casesNo. exposedpublication bias
Maternal liver disorder / failure during pregnancy--0 study
Preeclampsia1.13 [0.13, 10.01]0%2 studies4310not evaluable
2 non statistically significant endpoints reported in only one study

Neonatal disorders
Adverse outcome VerdictOR 95%CI I2k No. casesNo. exposedpublication bias
Goiter2.03 [0.18, 23.21]57%3 studies27170not evaluable
Hypothyroidism (fetal/neonatal)2.54 [0.51, 12.61]6%4 studies11346not evaluable
Hyperthyroidism / Thyrotoxicosis (fetal/neonatal)3.27 [0.40, 26.43]40%3 studies15204not evaluable
Neonatal hyperthyrotropinemia3.02 [1.04, 8.78]-1 study18111not evaluable
Neonatal death--0 study
3 non statistically significant endpoints reported in only one study

Long term consequences
Adverse outcome VerdictOR 95%CI I2k No. casesNo. exposedpublication bias
Neuro-developmental disorders5.34 [2.17, 13.10]-1 study69220not evaluable

Intrauterine deaths
Adverse outcome VerdictOR 95%CI I2k No. casesNo. exposedpublication bias
Early intrauterine death (< 22 weeks)1.89 [0.68, 5.24]85%4 studies5803,399not evaluable
Intrauterine deaths (as a whole)1.41 [0.88, 2.25]0%5 studies86435not evaluable
Elective termination of pregnancy1.97 [1.17, 3.33]0%3 studies993,295not evaluable
Late intrauterine deaths (> 22 weeks)0.20 [0.01, 6.47]74%2 studies9167not evaluable
Perinatal death0.76 [0.36, 1.56]0%3 studies293,350not evaluable
Ectopic pregnancy--0 study

- About - Master protocol - Browse exposition - RSS - Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons